BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 11927521)

  • 1. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
    Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
    Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt.
    Fukazawa R; Miller TA; Kuramochi Y; Frantz S; Kim YD; Marchionni MA; Kelly RA; Sawyer DB
    J Mol Cell Cardiol; 2003 Dec; 35(12):1473-9. PubMed ID: 14654373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
    Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
    Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes.
    Pentassuglia L; Timolati F; Seifriz F; Abudukadier K; Suter TM; Zuppinger C
    Exp Cell Res; 2007 May; 313(8):1588-601. PubMed ID: 17400210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes.
    Timolati F; Ott D; Pentassuglia L; Giraud MN; Perriard JC; Suter TM; Zuppinger C
    J Mol Cell Cardiol; 2006 Nov; 41(5):845-54. PubMed ID: 17005195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling.
    Kuramochi Y; Cote GM; Guo X; Lebrasseur NK; Cui L; Liao R; Sawyer DB
    J Biol Chem; 2004 Dec; 279(49):51141-7. PubMed ID: 15385548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
    Schneider JW; Chang AY; Rocco TP
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes.
    Kuramochi Y; Guo X; Sawyer DB
    J Mol Cell Cardiol; 2006 Aug; 41(2):228-35. PubMed ID: 16769082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
    Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
    Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes.
    Pentassuglia L; Graf M; Lane H; Kuramochi Y; Cote G; Timolati F; Sawyer DB; Zuppinger C; Suter TM
    Exp Cell Res; 2009 Apr; 315(7):1302-12. PubMed ID: 19331811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins.
    Bian Y; Sun M; Silver M; Ho KK; Marchionni MA; Caggiano AO; Stone JR; Amende I; Hampton TG; Morgan JP; Yan X
    Am J Physiol Heart Circ Physiol; 2009 Dec; 297(6):H1974-83. PubMed ID: 19801490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
    Longva KE; Pedersen NM; Haslekås C; Stang E; Madshus IH
    Int J Cancer; 2005 Sep; 116(3):359-67. PubMed ID: 15800944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK.
    Baliga RR; Pimental DR; Zhao YY; Simmons WW; Marchionni MA; Sawyer DB; Kelly RA
    Am J Physiol; 1999 Nov; 277(5):H2026-37. PubMed ID: 10564160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic Evidence of MSCs-Derived Exosomes in Doxorubicin/Trastuzumab-Induced Cardiotoxicity: Beyond Mechanistic Target of NRG-1/Erb Signaling Pathway.
    Ebrahim N; Al Saihati HA; Mostafa O; Hassouna A; Abdulsamea S; Abd El Aziz M El Gebaly E; Abo-Rayah NH; Sabry D; El-Sherbiny M; Madboly AG; Hussien NI; Saadani REH; Ebrahim HA; Badr OAM; Elsherbiny NM; Salim RF
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.
    Seemann I; te Poele JA; Song JY; Hoving S; Russell NS; Stewart FA
    Breast Cancer Res Treat; 2013 Oct; 141(3):385-95. PubMed ID: 24091769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction and inhibitory cross-talk between endothelin and ErbB receptors in the adult heart.
    Chung KY; Walker JW
    Mol Pharmacol; 2007 Jun; 71(6):1494-502. PubMed ID: 17332141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuregulin-1 enhances survival of human astrocytic glioma cells.
    Ritch PS; Carroll SL; Sontheimer H
    Glia; 2005 Aug; 51(3):217-28. PubMed ID: 15812817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model.
    Hermes M; Schormann W; Brulport M; Uhlemann K; Lupatsch F; Horn LC; Schumann A; Allgaier C; Weishaupt M; Engeland K; Müller GA; Mössner J; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Lausch E; Prawitt D; Wilhelm C; Hengstler JG
    Br J Cancer; 2008 May; 98(9):1525-32. PubMed ID: 18454161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.
    Jay SM; Murthy AC; Hawkins JF; Wortzel JR; Steinhauser ML; Alvarez LM; Gannon J; Macrae CA; Griffith LG; Lee RT
    Circulation; 2013 Jul; 128(2):152-61. PubMed ID: 23757312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.